Phillies could add Mike Adams to bullpen Monday

1 Comment

Mike Adams has been sidelined since undergoing shoulder surgery in July, but the Phillies reliever could be cleared to come off the disabled list as soon as Monday if a weekend minor-league rehab appearance at Triple-A goes well.

Adams signed a two-year, $12 million deal with the Phillies last offseason after a five-year run as a dominant setup man for the Padres and Rangers, but wasn’t his usual self last season in 28 appearances before being shut down.

Interestingly, Todd Zolecki of MLB.com reports that Adams’ velocity has been in the high-80s during his recent Single-A game action, which is a few miles per hour off from his Padres/Rangers days, and the right-hander seems sort of resigned to no longer throwing as hard at age 35. So expectations should probably be held in check.

Rays trade Jake Odorizzi to Twins

Getty Images
4 Comments

The Rays have traded right-hander Jake Odorizzi to the Twins, per team announcements on Saturday evening. The Twins will receive minor league shortstop Jermaine Palacios in the deal. Despite previous speculation, recently-DFA’d outfielder Corey Dickerson was not included in the trade.

With Odorizzi, the Twins finally have the front-end starter they’ve been seeking all winter. It’s a bargain deal as well, as the 27-year-old righty is under contract through 2019 and didn’t require the club to part with any of their top-shelf prospects in the trade. Odorizzi will be looking to stage a comeback in 2018 after a dismal performance with the Rays last year, during which he eked out a career-worst 4.14 ERA, 3.8 BB/9 and 8.0 SO/9 through 143 1/3 innings.

Palacios, 21, ranked no. 27 in the Twins’ system last season. He split his year between Single-A Cedar Rapids and High-A Fort Myers, raking a combined .296/.333/.454 with 13 home runs and 20 stolen bases in 539 plate appearances. He’s expected to continue developing at shortstop, though he’s also seen limited time at second and third base during his four-year career in the minors.